Full Breakdown
QuidelOrtho Explores $1.5 B Sale of Point-of-Care Testing Unit
6/27/2026, 11:24:53 PM
Sale Announcement and Valuation
QuidelOrtho Corp, a San Diego-based diagnostics firm listed in New York, is actively seeking a buyer for its point-of-care (POC) testing unit. The Financial Times reports that the unit is being marketed at a valuation of $1.5 billion. Sale discussions are described as “advanced,” but the same source notes that no guarantee exists that a transaction will close.
Company Background and Testing Portfolio
Formed in 2022 through the merger of Quidel Corporation and Ortho Clinical Diagnostics, QuidelOrtho provides diagnostic, tracking, and analytical services for a range of health conditions, including HIV, hepatitis C, and COVID-19. During the COVID-19 pandemic, the combined company secured the first full FDA clearance for a rapid antigen COVID-19 test, underscoring its role in rapid diagnostics.
Financial Context and Revenue Share
Bloomberg data lists QuidelOrtho’s enterprise value at $3.64 billion. The POC testing unit contributed 22 % of total revenues in 2025, according to an investor presentation. If the $1.5 billion valuation materializes, the divestiture would represent roughly 41 % of the company’s overall enterprise value, highlighting the unit’s strategic weight within the firm’s portfolio.
Private-Equity Interest
The FT cites interest from several private-equity firms, specifically Advent International, SK Capital Partners, and Archimed. The phrasing “ranging from … to … and …” suggests a broader pool of potential bidders, though no additional names are disclosed.
Official Statements & Responses
QuidelOrtho has not issued a public comment on the prospective sale. Bloomberg’s request for comment went unanswered, and the Financial Times emphasizes that the reported valuation and buyer interest are based on sources familiar with the matter rather than official company disclosures. The firm’s silence leaves the transaction’s timeline and terms unconfirmed.
Criticism & Opposition
No source material presents explicit criticism or opposition to the proposed sale. Consequently, the article does not identify organized dissent from shareholders, regulators, or industry groups.
Conflicting Reports & Gaps
- Deal certainty: The Financial Times qualifies the talks as “advanced” yet stresses the lack of a guaranteed outcome.
- Company response: Absence of an official statement from QuidelOrtho creates uncertainty about strategic intent and valuation justification.
- Buyer list: Only three private-equity firms are named, leaving the full scope of interested parties unclear.
Verbatim Quotes
- “Private equity firms ranging from Advent International to SK Capital Partners and Archimed have expressed interest in the asset, according to the FT report, which cited people familiar with the matter.” — Financial Times
- “While sale talks are advanced, there is no guarantee that they will yield a deal, the FT said.” — Financial Times
- “Representatives for QuidelOrtho didn’t immediately respond to a request for comment from Bloomberg News.” — Bloomberg News
What’s Next
The next steps depend on whether a private-equity bidder finalizes a purchase agreement. Potential outcomes include a completed sale that would reshape QuidelOrtho’s revenue composition, or a withdrawal of interest that could prompt the company to retain the POC unit and explore alternative growth strategies. No specific timeline for a decision has been disclosed.
